GlassScriptPhysician profile
Mark J Stewart
NPI 1225114051
$3,293.49
in general payments reported to CMS, 2019-2025
37 companies · $435 in 2025
The $435 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $259 · 2021: $713 · 2022: $522 · 2023: $458 · 2024: $455 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $481.85 | 2021-2025 | General - Pain Management, Wavewriter Alpha Prime 16, General - Therapies |
| Scilex Pharmaceuticals INC. | $448.30 | 2019-2024 | Ztlido |
| Ibsa Pharma INC. | $295.65 | 2020-2025 | Tirosint, Licart, Flector |
| Collegium Pharmaceutical, INC. | $242.40 | 2019-2025 | Xtampza, Belbuca |
| Medtronic, INC. | $179.39 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Arbor Pharmaceuticals, INC. | $164.73 | 2019-2022 | |
| Forte Bio-Pharma LLC | $163.64 | 2020-2024 | Prolate, Nalocet |
| Nevro Corp. | $162.26 | 2020-2023 | Senza |
| Biodelivery Sciences International, INC. | $124.17 | 2020-2021 | |
| Lemaitre Vascular, INC. | $110.42 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.02 | 2019-2025 | Relistor |
| Azurity Pharmaceuticals, INC. | $90.21 | 2023-2025 | Horizant, Horizant |
| Amgen INC. | $76.96 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $66.28 | 2022-2024 | Quviviq |
| Lilly USA, LLC | $54.59 | 2020-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $49.87 | 2021-2022 | |
| Biotronik Nro, INC. | $37.97 | 2024-2025 | Prospera |
| Pfizer INC. | $35.35 | 2020-2021 | |
| Horizon Therapeutics Plc | $32.21 | 2019-2022 | |
| Avanos Medical | $29.11 | 2020-2021 | |
| Medtronic USA, INC. | $27.95 | 2020 | |
| Bioventus LLC | $25.11 | 2022 | |
| Masimo Corporation | $24.44 | 2023 | Patient Safetynet System |
| Takeda Pharmaceuticals U.S.A., INC. | $24.31 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $22.56 | 2019 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $20.92 | 2025 | Iovera, Zilretta |
| Averitas Pharma INC. | $20.44 | 2023 | Qutenza |
| Supernus Pharmaceuticals, INC. | $20.06 | 2019 | |
| Abbvie INC. | $19.68 | 2021 | |
| Daiichi Sankyo INC. | $19.34 | 2019 | |
| Spinal Simplicity, LLC | $17.80 | 2025 | Ha Minuteman G3-R |
| Bausch Health US, LLC | $17.37 | 2019 | |
| Merz North America, INC. | $16.57 | 2019 | |
| Stimwave Technologies Incorporated | $15.98 | 2021 | |
| Protega Pharmaceutials INC | $15.91 | 2023 | Roxybond |
| Novartis Pharmaceuticals Corporation | $12.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.